Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H19NO4.ClH |
| Molecular Weight | 337.798 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=C(COCCN)C2=CC3=C(OC(=O)C=C3C)C(C)=C2O1
InChI
InChIKey=MHLAMQBABOJZQW-UHFFFAOYSA-N
InChI=1S/C17H19NO4.ClH/c1-9-6-15(19)22-16-10(2)17-13(7-12(9)16)14(11(3)21-17)8-20-5-4-18;/h6-7H,4-5,8,18H2,1-3H3;1H
| Molecular Formula | C17H19NO4 |
| Molecular Weight | 301.3371 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Amotosalen (S-59, psoralen derivative), a chemical capable of binding to nucleic acids is added to platelets. UVA illumination (320 – 400 nm wavelengths) of amotosalen-treated platelet components induces covalent cross-linking of any nucleic acids to which amotosalen is bound; thereby, preventing further replication. Amotosalen is used in the INTERCEPT process to cross-link DNA and RNA. Amotosalen has protective activity against pathogens such as bacteria, viruses, protozoa, and leukocytes. Prior to administration amotosalen is added to plasma and platelets, then in vivo this agent penetrates pathogens and targets DNA and RNA. Upon activation by ultraviolet A light, amotosalen forms interstrand DNA and RNA crosslinks and prevents replication. Thus, the pathogen-inactivation system using amotosalen/ultraviolet A offers the potential to mitigate the risk of ZIKV transmission by plasma and platelet transfusion. Inactivation of leukocytes can prevent graft versus host disease upon transfusion.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Monitoring photochemical pathogen inactivation treatment using amotosalen and ultraviolet-A light: evaluation of an indicator label. | 2010-11 |
|
| The how's and why's of evidence based plasma therapy. | 2010-09 |
|
| Transfusion-transmitted parasitic infections. | 2010-07 |
|
| An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. | 2010-06 |
|
| INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function--an in vitro analysis. | 2010-01 |
|
| Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats. | 2009-05 |
|
| Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light. | 2009-04 |
|
| Quantitative analysis of DNA interstrand cross-links and monoadducts formed in human cells induced by psoralens and UVA irradiation. | 2008-11-15 |
|
| Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments. | 2008-10 |
|
| Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. | 2008-08 |
|
| A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. | 2008-06 |
|
| An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. | 2008-05 |
|
| Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. | 2008-04 |
|
| Effects of intercept pathogen inactivation on platelet function as analysed by free oscillation rheometry. | 2008-02 |
|
| Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. | 2008-01 |
|
| Evaluation of bacterial inactivation in prestorage pooled, leukoreduced, whole blood-derived platelet concentrates suspended in plasma prepared with photochemical treatment. | 2007-10 |
|
| Transfusion-transmitted infections. | 2007-06-06 |
|
| Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination. | 2007-06 |
|
| Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions. | 2007-04 |
|
| The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy-coat platelets. | 2007-03 |
|
| Quantification of viral inactivation by photochemical treatment with amotosalen and UV A light, using a novel polymerase chain reaction inhibition method with preamplification. | 2006-12-15 |
|
| A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. | 2006-10 |
|
| Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. | 2006-07 |
|
| Risks of fresh frozen plasma and platelets. | 2006-06 |
|
| Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage. | 2006-05 |
|
| Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. | 2006-05 |
|
| Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial. | 2006-04 |
|
| Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. | 2006-03 |
|
| In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set. | 2006-02 |
|
| Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. | 2006-01 |
|
| The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections. | 2006-01 |
|
| Pathogen inactivation techniques. | 2006 |
|
| Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. | 2005-12 |
|
| Effect of the psoralen-based photochemical pathogen inactivation on mitochondrial DNA in platelets. | 2005-12 |
|
| Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. | 2005-10 |
|
| Polymerase chain reaction inhibition assay documenting the amotosalen-based photochemical pathogen inactivation process of platelet concentrates. | 2005-09 |
|
| Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. | 2005-09 |
|
| Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. | 2005-09 |
|
| Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. | 2005-08 |
|
| Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. | 2005-08 |
|
| In vitro photochemical inactivation of cell-associated human T-cell leukemia virus Type I and II in human platelet concentrates and plasma by use of amotosalen. | 2005-07 |
|
| Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. | 2005-04 |
|
| Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation. | 2005-03 |
|
| Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. | 2004-12 |
|
| Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. | 2004-10 |
|
| Facilitating T-cell immune reconstitution after haploidentical transplantation in adults. | 2004-07-07 |
|
| Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. | 2004-05 |
|
| In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen. | 2004-04 |
|
| Functional characteristics of photochemically treated platelets. | 2004-03 |
|
| In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days. | 2004 |
Patents
Sample Use Guides
Using the LDA assay, treatment with 150 uM of
amotosalen and 1.0–3.0 J/cm2 UVA light inactivated
>5.4 – 0.3 log of T cells in single donor plateletpheresis
units. The minimum concentration of amotosalen required to inactivate T cells after illumination with 1 J/cm2 of UVA light was 0.05 uM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:58:08 GMT 2025
by
admin
on
Mon Mar 31 17:58:08 GMT 2025
|
| Record UNII |
67B255SI5F
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C582
Created by
admin on Mon Mar 31 17:58:08 GMT 2025 , Edited by admin on Mon Mar 31 17:58:08 GMT 2025
|
||
|
NCI_THESAURUS |
C25760
Created by
admin on Mon Mar 31 17:58:08 GMT 2025 , Edited by admin on Mon Mar 31 17:58:08 GMT 2025
|
||
|
NCI_THESAURUS |
C2163
Created by
admin on Mon Mar 31 17:58:08 GMT 2025 , Edited by admin on Mon Mar 31 17:58:08 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C72699
Created by
admin on Mon Mar 31 17:58:08 GMT 2025 , Edited by admin on Mon Mar 31 17:58:08 GMT 2025
|
PRIMARY | |||
|
159598
Created by
admin on Mon Mar 31 17:58:08 GMT 2025 , Edited by admin on Mon Mar 31 17:58:08 GMT 2025
|
PRIMARY | |||
|
300000044601
Created by
admin on Mon Mar 31 17:58:08 GMT 2025 , Edited by admin on Mon Mar 31 17:58:08 GMT 2025
|
PRIMARY | |||
|
67B255SI5F
Created by
admin on Mon Mar 31 17:58:08 GMT 2025 , Edited by admin on Mon Mar 31 17:58:08 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110621
Created by
admin on Mon Mar 31 17:58:08 GMT 2025 , Edited by admin on Mon Mar 31 17:58:08 GMT 2025
|
PRIMARY | |||
|
161262-45-9
Created by
admin on Mon Mar 31 17:58:08 GMT 2025 , Edited by admin on Mon Mar 31 17:58:08 GMT 2025
|
PRIMARY | |||
|
DTXSID70167093
Created by
admin on Mon Mar 31 17:58:08 GMT 2025 , Edited by admin on Mon Mar 31 17:58:08 GMT 2025
|
PRIMARY | |||
|
MM-24
Created by
admin on Mon Mar 31 17:58:08 GMT 2025 , Edited by admin on Mon Mar 31 17:58:08 GMT 2025
|
PRIMARY | |||
|
C118577
Created by
admin on Mon Mar 31 17:58:08 GMT 2025 , Edited by admin on Mon Mar 31 17:58:08 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |